Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $16.68, but opened at $15.82. Bolt Biotherapeutics shares last traded at $15.44, with a volume of 1,808 shares traded.
A number of analysts recently weighed in on the stock. SVB Leerink upped their target price on shares of Bolt Biotherapeutics from $34.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, August 16th. Zacks Investment Research cut shares of Bolt Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 17th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $40.50.
The company has a debt-to-equity ratio of 0.08, a current ratio of 12.89 and a quick ratio of 12.89. The stock has a market capitalization of $594.10 million and a P/E ratio of -0.72. The company’s 50 day simple moving average is $14.24 and its two-hundred day simple moving average is $20.16.
Several hedge funds have recently made changes to their positions in the company. Novo Holdings A S acquired a new position in shares of Bolt Biotherapeutics during the first quarter worth approximately $148,226,000. Vivo Capital LLC acquired a new position in shares of Bolt Biotherapeutics during the first quarter worth approximately $127,404,000. Citadel Advisors LLC lifted its position in shares of Bolt Biotherapeutics by 1.3% during the second quarter. Citadel Advisors LLC now owns 2,960,154 shares of the company’s stock worth $44,856,000 after purchasing an additional 36,757 shares in the last quarter. RA Capital Management L.P. acquired a new position in shares of Bolt Biotherapeutics during the first quarter worth approximately $78,271,000. Finally, Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in shares of Bolt Biotherapeutics during the first quarter worth approximately $62,248,000. Institutional investors own 86.36% of the company’s stock.
Bolt Biotherapeutics Company Profile (NASDAQ:BOLT)
Bolt Biotherapeutics, Inc, a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers.
Recommended Story: Conference Calls and Individual Investors
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.